RxDoctor Payments Data

Robert Rubin

Nephrology · Washington, DCNPI 1013917749

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $113,700 of the $118,597 with a category attached, or 95.9%. Amgen accounts for 99.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $54,958 and has fallen 99.7% since, to $145 in 2023. Among nephrology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$118,597in general payments, 2019–2025

Across 56 payments — averaging $2117.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$118K
  • Vifor Pharma, Inc.$145

What the payments were for

  • Consulting fees$113,70096%
  • Travel & lodging$4,0823%
  • Food & beverage$8151%

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen55$118,453
Vifor Pharma, Inc.1$145

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,597 in reported general payments places this provider in the 95th percentile of 62 nephrology providers in District of Columbia.

See all nephrology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$17,043
Medicare patients
57
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Torsemide12$218

Paid to pharmacies, not to this prescriber.

Other nephrology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →